Stephen Hoge Sells 53,336 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $48.40, for a total value of $2,581,462.40. Following the transaction, the president owned 1,477,997 shares of the company’s stock, valued at $71,535,054.80. The trade was a 3.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Monday, February 23rd, Stephen Hoge sold 160,009 shares of Moderna stock. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56.

Moderna Stock Performance

NASDAQ MRNA opened at $45.72 on Wednesday. The stock has a 50-day simple moving average of $51.31 and a two-hundred day simple moving average of $41.27. The firm has a market capitalization of $18.14 billion, a P/E ratio of -5.61 and a beta of 1.05. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $59.55. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million for the quarter, compared to analysts’ expectations of $236.37 million. During the same quarter in the previous year, the business posted ($2.52) EPS. The business’s quarterly revenue was up 260.2% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -6.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several recent analyst reports. Royal Bank Of Canada lifted their price target on Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research note on Monday, May 4th. Jefferies Financial Group set a $37.00 price target on Moderna and gave the company a “hold” rating in a research note on Tuesday, March 3rd. UBS Group lifted their price target on Moderna from $36.00 to $45.00 and gave the company a “neutral” rating in a research note on Monday, May 4th. TD Cowen restated a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Finally, Leerink Partners restated an “underperform” rating on shares of Moderna in a research note on Friday, January 30th. Two equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have issued a Sell rating to the company. According to data from MarketBeat, Moderna has an average rating of “Reduce” and a consensus target price of $35.73.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. MUFG Securities EMEA plc acquired a new position in shares of Moderna during the 2nd quarter worth approximately $28,000. Flagship Harbor Advisors LLC acquired a new position in shares of Moderna during the 4th quarter worth approximately $31,000. Canton Hathaway LLC purchased a new stake in shares of Moderna during the 1st quarter valued at approximately $31,000. Ameriflex Group Inc. raised its position in shares of Moderna by 3,775.0% during the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after buying an additional 1,208 shares during the period. Finally, Cromwell Holdings LLC raised its position in shares of Moderna by 39.7% during the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after buying an additional 341 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.